“Spring is the time of plans and projects.”
– Leo Tolstoy
The Thrombosis Research Institute is dedicated to bringing new solutions to patients for the detection, prevention and treatment of blood clots. Our programme of research was first established in the 1960s and since then our work has changed the lives of those at risk of thrombosis through the use heparin for its prevention, and the pioneering use of the low molecular weight heparins. Today we remain one of the few academic research institutes solely devoted to working in thrombosis.
At TRI, our research is driven by the needs of patients so that innovations and new treatments flow seamlessly from theory to practice. TRI has become a world leader in the developing field of real-world outcomes research, developing and executing pioneering global programmes.
Our success comes through partnership with a network of more than 2,500 research centres in around 40 countries. Bringing the quality of our data and the rigour of clinical trials to real-world studies, our operation models have extended quality research to under-represented countries, care settings and patients. Through our registries, we seek to strengthen the chain of evidence beyond clinical trials and hope to create new data to improve healthcare delivery and patient outcomes.
The Thrombosis Research Institute is investigating emerging health technologies, including Artificial Intelligence and Machine Learning, which are providing data-driven insights on clinical care. We envision a future using intelligent modelling and “big data” from apps and the web to develop cutting edge models for connected care.View brochure
The pioneering programme of research now recognisable as TRI was established. It delivered breakthrough solutions in thrombosis which have saved millions of lives and this innovation continues today, across medical disciplines and around the world.
TRI was established as an independant institute, with the backing of the then Prime Minister, Margaret Thatcher, specifically to conduct research into thrombosis, a major cause of death and disability throughout the world.
TRI is now acknowledged as a leader in clinical research and real-world evidence, bringing the quality of data and rigour of clinical trials to real-world studies, and shaping the design of new registries.
Vijay Kakkar was Founder of the Thrombosis Research Institute, London and Founder, Scientific Chairman and Managing Trustee of the Thrombosis Research Institute, Bangalore and Emeritus Professor of the University of London.
He was the recipient of a number of distinctions and awards including:
A Hunterian Professorship from the Royal College of Surgeons, the Gunnar Bayer Memorial Lecture, the David Patey Prize of the Surgical Society of Great Britain and Ireland, Visiting Professor of Harvard University, the James Finalyson Memorial Lecture, the Cross Memorial Lecture, the Wright-Schultz award from the International Society of Thrombosis and Haemostasis for original and outstanding contribution in Thrombosis Research, the Freyer Memorial Lecture, Hon Fellowships of the Academy of Medicine in Singapore and the Association of Surgeons of India, a lifetime achievement award from the International Union of Angiology for outstanding leadership in the investigation of thrombotic disorders and an annual award for medicine from the Guild of British Asians for outstanding contribution by Asian doctors to British medicine.
He was Founder President of the British Society of Haemostasis and Thrombosis and Founder President of the South Asian Society of Atherosclerosis and Thrombosis.
On his retirement from the University in 1997, he was awarded the title of Emeritus Professor of the University of London. His publications include over 680 original articles, six books and contributions to 44 text books.
At the Thrombosis Research Institute, we are committed to saving millions of lives, preventing long term disability and reducing healthcare costs by delivering pioneering advances in the detection, prevention and treatment of thrombosis.
The institutes’ research activities encompass drug discovery basic science and clinical research, and epidemiology studies. We are primarily concerned with understanding the disease process, developing novel and affordable therapies and identifying those most at risk at an early age.
We are also closely involved with promoting take up of evidence based methods of prevention and treatment to ensure that knowledge from ground breaking research quickly informs clinical practice and benefits patients as soon as possible.
Our multidisciplinary programme of laboratory and clinical research has contributed to major advances in venous thromboembolism that have changed clinical practice.
Thrombosis research related to the early detection, prevention and treatment of post-operative venous thromboembolism was started in 1965 with a staff group of two. Work conducted by the Institute’s Founder, Professor Vijay Kakkar describing the natural history of deep vein thrombosis in surgical patients was among the first to identify the magnitude of this now widely recognised problem (1969). By describing the cause and effect of venous thromboembolism, he demonstrated for the first time the extent of the problem and the impact for surgical patients of pulmonary embolism.
Having defined the problems of venous thromboembolism, Professor Vijay Kakkar then pioneered new methods for its detection, prevention and treatment. In the early 1970s, he established that deep vein thrombosis / pulmonary embolism could be prevented in surgical patients by using a fixed low dose of heparin, an anticoagulant.
In 1975, a major mortality outcome study ‘The International Multicentre Trial’ (Kakkar W, et al. 1975 Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Lancet, 306: 45-64) coordinated by the Thrombosis Research Institute validated Professor Kakkar’s original research into the prevention of peri- and post-operative death from pulmonary embolism. This trial, considered the seminal work in the field, found that heparin prophylaxis reduces death from pulmonary embolism, saving seven lives for every 1,000 operated patients.
In 1982, the first clinical evaluation of low molecular weight heparin in the prevention of deep vein thrombosis was published by staff at the Institute. Since then, a continuous programme of basic and clinical research has further evaluated these agents for the prevention of both arterial and venous thromboembolism, helping to establish low molecular weight heparins as the gold standard for antithrombotic therapy over several decades.
These methods are now used throughout the world and have resulted in the near eradication of deaths due to thrombosis in high risk patients undergoing major surgery, saving approximately 300,000 lives per year worldwide.
The Thrombosis Research Institute is among only a handful of organisations in the world undertaking a multidisciplinary approach to thrombosis research by bringing together clinicians and scientists involved in basic research.
Both Institutes employ approximately 50 staff, and are:
The Director of the Thrombosis Research Institute, London is Professor the Lord Kakkar, who was principally responsible for the implementation of policies agreed by the Board of Trustees for the Institute in London. The Deputy Director and Chief Operating Officer is Ms Gloria Kayani.
The Founder and President of the Thrombosis Research Institute, London and Founder, Scientific Chairman and Managing Trustee of the Thrombosis Research Institute, Bangalore was Professor Vijay Kakkar OBE.
Mr Patrick Burgess (Chairman)
Miss Joanna Kaye
Mr Guy Weston
Dr Jeffrey Herbert
Sir Martin Sorrell
As well as Director of the Thrombosis Research Institute, London, Ajay Kakkar is Professor of Surgery at University College London, Consultant Surgeon University College Hospitals NHS Foundation Trust, and Chair for Clinical Quality University College London Partners. Academic Health Science System. He received his medical education at King’s College Hospital Medical School, University of London, BSc 1985, MBBS (Hons) 1988, received a PhD in 1998 from Imperial College London. He was made a fellow of the Royal College of Surgeons of England in 1992.
His awards include Hunterian Professor, Royal College of Surgeons of England 1996, the David Patey Prize, Surgical Research Society of Great Britain and Ireland 1996, the Knoll William Harvey Prize, International Society on Thrombosis and Haemostasis 1997, the James IV Association of Surgeons travelling fellow in 2006, Welcome Lecture and Royal Society of Medicine 2009.
Lord Kakkar’s research interests are in the prevention and treatment of venous thromboembolic disease and cancer-associated thrombosis and, in particular, the role of antithrombotic therapy in prolonging survival in cancer and the role of coagulation serine proteases in tumour biology.
Gloria Kayani graduated with a degree in Medical Biochemistry and has pursued a career in clinical research. She spent 15 years in various leadership and clinical operations roles at GlaxoSmithKline and Roche, managing cross functional and international clinical teams.
Currently as Deputy Director/COO at the Thrombosis Research Institute (TRI), she has operational responsibility for implementing and delivering TRI’s extensive international clinical and science research programmes. She works closely with global experts and key opinion leaders in the thrombosis and cardiovascular medicine fields to deliver high quality projects.
HRH The Prince Philip Duke of Edinburgh KG KT
The Most Hon The Marquess of Salisbury KCVO PC DL (Chairman)
Sir Michael Edwardes
Sir David McDonough OBE
Mr Björn Saven
Sir Julian Seymour CBE
The Lord Sherbourne of Didsbury CBE
Sir Mark Worthington OBE
Patrick Burgess MBEOBE DL (Chairman)
Dr Jeffrey Herbert
Miss Joanna Kaye
Sir Martin Sorrell
TRI has its own independent clinical research and development facility and is well known for excellent collaboration with leading research institutions and universities in the UK and around the world. We have access to the very best international researchers and research programmes through this wide range of partnerships. The institute’s research programmes also benefit from a well-established network of some 2,500 research sites in around 40 countries. They are central to the registries and observational studies that are conducted under the auspices of TRI, and are led by scientific steering committees and national coordinating councils comprising some of the best experts in thrombosis from around the world.